Genomic medicine and risk prediction across the disease spectrum

Critical Reviews in Clinical Laboratory Sciences

Volumn 52, Issue 3, 2015, Pages 120-137

  Kotze, Maritha J ^a   Lückhoff, Hilmar K ^a   Peeters, Armand V ^a   Baatjes, Karin ^a   Schoeman, Mardelle ^a   Van Der Merwe, Lize ^a,b   Grant, Kathleen A ^a,c   Fisher, Leslie R ^a   Van Der Merwe, Nicole ^a   Pretorius, Jacobus ^a   Van Velden, David P ^a   Myburgh, Ettienne J ^d   Pienaar, Fredrieka M ^d   Van Rensburg, Susan J ^a   Yako, Yandiswa Y ^a   September, Alison V ^e   Moremi, Kelebogile E ^a   Cronje, Frans J ^a   Tiffin, Nicki ^b   Bouwens, Christianne S H ^a   Bezuidenhout, Juanita ^a   Apffelstaedt, Justus P ^a   Hough, F Stephen ^a   Erasmus, Rajiv T ^d   Schneider, Johann W ^a   more..

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^c CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^d Panorama Medi Clinic   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Breast cancer; database; exome; genome; hg19; major allele reference sequence; metabolic syndrome; multiple sclerosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN E4; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMETABOLIC RISK; CHRONIC DISEASE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DYSLIPIDEMIA; ENVIRONMENTAL EXPOSURE; EXOME; FAMILY HISTORY; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; HYPERTENSION; METABOLIC SYNDROME X; MONOGENIC DISORDER; MULTIPLE SCLEROSIS; NEXT GENERATION SEQUENCING; NON COMMUNICABLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY SUPPORTED GENETIC TESTING; PATIENT CARE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SOUTH AFRICAN; TRIPLE NEGATIVE BREAST CANCER; WHOLE GENOME SEQUENCING; ETHICS; EVIDENCE BASED MEDICINE; FAMILY HEALTH; GENETIC DATABASE; GENETIC PREDISPOSITION; GENOMICS; PROCEDURES;

DATABASES, GENETIC; EVIDENCE-BASED MEDICINE; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; PRECISION MEDICINE;

EID: 84929792095     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2014.997930     Document Type: Review

References (130)

1. Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-5
2. Janssens CJW, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008; 17: 166-73
3. Hood L. Systems biology and P4 medicine: past, present and future. Rambam Maimonides Med J 2013; 4: e0012
4. Myers RH. Huntingtons disease genetics. NeuroRx 2004; 1: 255-62
5. Weitzel JN, Blazer KR, Macdonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011; 61: 327-59
6. Khoury MJ, Berg A, Coates R, et al. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008; 27: 1600-11
7. Cornel MC, van El CG, Borry P. The challenge of implementing genetic tests with clinical utility while avoiding unsound applications. J Community Genet 2014; 5: 7-12
8. Kotze MJ, van Velden DP, Botha K, et al. Pathology-supported genetic testing directed at shared disease pathways for optimized health in later life. Personalized Med 2013; 10: 497-507
9. Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 2012; 15: 1162-71
10. Azim HA Jr, Michiels S, Zagouri F, et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013; 24: 647-54
11. Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS One 2009; 4: e4346
12. Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimers and Huntingtons diseases: shared targets for drug development. Nat Rev Drug Discov 2011; 10: 853-67
13. Li Y, Huang T, Xiao Y, et al. Prioritising risk pathways of complex human diseases based on functional profiling. Eur J Hum Genet 2013; 21: 666-72
14. Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet 2012; 13: 135-45
15. Wagner MJ. Rare-variant genome-wide association studies: a new frontier in genetic analysis of complex traits. Pharmacogenomics 2013; 14: 413-24
16. Donahue MP, Marchuk DA, Rockman HA. Redefining heart failure: the utility of genomics. J Am Coll Cardiol 2006; 48: 1289-98
17. Brand A, Brand H, Schulte in den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet 2008; 16: 5-13
18. Kotze MJ, Van Velden DP, Van Rensburg SJ, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: new insights for clinical application. J Int Fed Clin Chem Lab Med 2009; 20: 1-15
19. Kotze MJ, van Rensburg SJ. Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimers disease. Metab Brain Dis 2012; 27: 255-66
20. Kotze MJ, Gamieldien J. Challenges, successes and current opportunities in whole exome sequencing. Specialist Forum 2013; 13: 6-7
21. Schoeman M, Apffelstaedt JP, Baatjes K, Urban M. Implementation of a breast cancer genetic service in South Africa-lessons learned. S Afr Med J 2013; 103: 529-33
22. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011; 17: 297-303
23. Grant KA, Apffelstaedt JP, Wright C, et al. MammaPrint Prescreen Algorithm (MPA) reduces chemotherapy in patients with early stage breast cancer. S Afr Med J 2013; 103: 522-6
24. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33
25. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89
26. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-47
27. Larsen MJ, Kruse TA, Tan Q, et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 2013; 8: e64268
28. Larsen MJ, Thomassen M, Tan Q, et al. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families. BMC Med Genomics 2014; 7: 9
29. Naushad SM, Pavani A, Rupasree Y, et al. Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer. Mol Carcinog 2012; 51: 32-41
30. Gracia-Aznarez FJ, Fernandez V, Pita G, et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 2013; 8: e55681
31. Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14: 5913-18
32. Jakubowska A, Gronwald J, Menkiszak J, et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 2007; 104: 299-308
33. Pepe C, Guidugli L, Sensi E, et al. Methyl group metabolism gene polymorphisms as modifiers of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Res Treat 2007; 103: 29-36
34. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121: 3786-8
35. Glück S, de Snoo F, Peeters J, et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013; 139: 759-67
36. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-53
37. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 2013; 20: 3254-8
38. Davis A, Raklamani V. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012: 1-10
39. Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22: 2687-92
40. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8: R38
41. De Leeneer K, Coene I, Crombez B, et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treat 2012; 132: 87-95
42. Van der Merwe N, Bouwens CSH, Pienaar R, et al. CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application. Metab Brain Dis 2012; 27: 319-26
43. Reeves MD, Yawitch TM, van der Merwe NC, et al. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 2004; 110: 677-82
44. Kotze MJ, Malan J, Pienaar R, Appfelstaedt J. The role of molecular genetic testing in modern breast health management. SA Fam Pract 2005; 47: 38-40
45. Knauer M, Mook S, Rutgers EJT, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120: 655-61
46. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119: 551-8
47. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133: 929-36
48. Drukker CA, van Tinteren H, Schmidt MK, et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 2014; 143: 587-92
49. Grant KA, Pienaar FM, Brundyn K, et al. Incorporating microarray assessment of HER2 status in clinical practice supports individualized therapy in early-stage breast cancer. Breast (in press)
50. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43
51. Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. Cancer Treat Rev 2014; 40: 276-84
52. Dabbs DJ, Klein ME, Mohsin SK, et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011; 29: 4279-85
53. Yamamoto-Ibusuki M, Yamamoto Y, Fu P, et al. Divisional role of quantitative HER2 testing in breast cancer. Breast Cancer 2013. [Epub ahead of print]
54. Park MM, Ebel JJ, Zhao W, Zynger DL. ER and PR immunohistochemistry and HER2 FISH versus Oncotype DX: implications for breast cancer treatment. Breast J 2014; 20: 37-45
55. Pohl EH, Myburgh EJ, Grant KA, et al. Cost-effective introduction of the 70-gene MammaPrint assay in South Africa and the impact on treatment decision making. Prevention of Prostate, Breast and Cervical Cancer in Africa Congress, 22 July 2014, Windhoek, Namibia
56. Grant K, Cronje FJ, Botha K, et al. Development of a genetic database resource for monitoring of breast cancer patients at risk of physical and psychological complications. S Afr J Psychiatry 2013; 19: 96-7
57. Phipps AI, Buist DS, Malone KE, et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat 2011; 126: 671-8
58. Bardia A, Arieas E, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012; 131: 907-14
59. Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009; 27: 5312-18
60. Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 2014; 46: 736-41
61. Ghadirian P, Narod S, Fafard E, et al. Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity. Breast Cancer Res Treat 2009; 17: 417-22
62. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-46
63. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-63
64. Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with metabolic syndrome. Diabetes Care 2005; 28: 1201-3
65. Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012; 35: 1171-80
66. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39: 306-18
67. Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-74
68. Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive decline among older women. Arch Neurol 2009; 66: 324-8
69. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 2012; 69: 741-62
70. Wens I, Dalgas U, Stenager E, Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis-a systematic review. Mult Scler 2013; 19: 1556-64
71. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol 2011; 25: 274-6
72. Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9-19
73. Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 2012; 8: 729-37
74. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Current Opinion Rheumatol 2008; 20: 187-91
75. Kim YJ, Kim CH, Sung EJ, et al. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013; 62: 808-13
76. Calvin AD, Albuquerque FN, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea, inflammation and the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 271-7
77. Davis W, van Rensburg SJ, Cronje FJ, et al. The fat mass and obesity-associated FTO rs9939609 polymorphism is associated with elevated homocysteine levels in patients with multiple sclerosis screened for vascular risk factors. Metab Brain Dis 2014; 29: 409-19
78. Delport D, Schoeman R, van der Merwe N, et al. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C > T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis 2014; 29: 377-84
79. Lückhoff HK, Van Rensburg SJ, Botha K, et al. The Pro-Inflammatory TNFA-308G > A (rs1800629) Polymorphism is associated with an earlier age at onset in patients with major depressive disorder. J Psychiatry 2014; 17: 1-6
80. Lückhoff HK, Brand T, van Velden DP, et al. Clinical relevance of apolipoprotein E genotyping based on a family history of Alzheimers disease. Curr Alz Res 2014 (in press)
81. Nelson MC, Isaacs F, Hassan MS, et al. Prevalence of abnormal blood flow patterns and effects of biochemistry and lifestyle factors on the major neck vessels in patients with Multiple Sclerosis in the Western Cape, South Africa. Med Tech SA 2014; 28: 26-33
82. van Velden DP, Kotze MJ, Blackhurst D, et al. Health claims and the benefits of moderate alcohol consumption in relation to genetic profiles. J Wine Res 2011; 22: 123-9
83. McIntyre RS, Park KY, Law CWY, et al. The association between conventional antidepressants and the metabolic syndrome. CNS Drugs 2010; 24: 741-53
84. Kotze MJ, Thiart R. Genetics of dyslipidaemia. CME J 2003; 21: 399-402
85. Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia-clinical and pathophysiological features. S Afr Med J 2002; 92: 892-7
86. Koruk M, Savaş MC, Yilmaz O, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003; 37: 177-82
87. Kruger FC, Daniels C, Kidd M, et al. Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis. S Afr Med J 2010; 100: 168-71
88. Shiri-Sverdlov R, Wouters K, van Gorp PJ, et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006; 44: 732-41
89. Zambón D, Quintana M, Mata P, et al. Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 2010; 123: 267-74
90. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008; 258: 28-47
91. Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis 2011; 10: 1-7
92. Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 2008; 12: 2762-71
93. Kotze MJ, de Villiers WJS, Steyn K, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993; 13: 1460-8
94. Kotze MJ, Lückhoff HK, Brand T, et al. Apolipoprotein ε-4 as a genetic determinant of Alzheimers disease heterogeneity. Degener Neurol Neuromuscul (in press)
95. Woods AG, Sokolowska I, Taurines R, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 2012; 16: 1184-95
96. Kotze MJ, Langenhoven E, Theart L, et al. Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners. Genet Counselling 1994; 5: 15-21
97. Sun X, Nicholas J, Walker A, et al. APOE genotype in the diagnosis of Alzheimers disease in patients with cognitive impairment. Am J Alzheimers Dis Other Demen 2012; 27: 315-20
98. Kotze MJ, Marnewick JL, Kidd M, et al. Assessment of the impact of hereditary factors on biochemical parameters of cardiovascular risk in relation to moderate alcohol consumption. Nutr Aging 2014; 2: 189-95
99. Djoussé L, Pankow JS, Arnett DK, et al. Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr 2004; 80: 1639-44
100. Corella D, Tucker K, Lahoz C, et al. Alcohol drinking determines the effect of the APOE locus on LDL-cholesterol concentrations in men: the Framingham Offspring Study. Am J Clin Nutr 2001; 73: 736-45
101. Cacabelos R, Martínez R, Fernández-Novoa L, et al. Genomics of dementia: APOE-and CYP2D6-related pharmacogenetics. Int J Alzheimers Dis 2012; 2012: 1-1-37
102. Frudakis TN, Thomas MJ, Ginjupalli SN, et al. CYP2D6 4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007; 17: 695-707
103. Brauch H, Schroth W, Goetz MP, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-80
104. Lou DI, Hussmann JA, McBee RM, et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. PNAS 2013; 110: 19872-7
105. Feero WG. Clinical application of whole-genome sequencing: proceed with care. JAMA 2014; 311: 1017-19
106. Bansal V, Libiger O, Torkamani A, Schork NJ. Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet 2010; 11: 773-85
107. Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012; 2012: 1-11
108. Tintle N, Aschard H, Hu I, et al. Inflated type I error rates when using aggregation methods to analyze rare variants in the 1000 Genomes Project exon sequencing data in unrelated individuals: summary results from Group 7 at Genetic Analysis Workshop 17. Genet Epidemiol 2011; 35: 56-60
109. Lyon GJ, Wang K. Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress. Genome Med 2012; 4: 1-16
110. Boland JF, Chung CC, Roberson D, et al. The new sequencer on the block: comparison of Life Technologys Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet 2013; 132: 1153-63
111. Jalali Sefid Dashti M, Kotze MJ, van Rensburg SJ, et al. Exome sequencing combined with semantic discovery identifies strong disease-associated candidates in a single case of relapsing remitting multiple sclerosis. BMC Proc 2012; 6: P10
112. ORawe J, Jiang T, Sun G, et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 2013; 5: 1-18
113. Kotze MJ, de Villiers JNP, Rooney RN, et al. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol Dis 2001; 27: 44-53
114. De Villiers JNP, Treurnicht FK, Warnich L, et al. Analysis of viral and genetic factors in South African patients with multiple sclerosis. Metab Brain Dis 2006; 21: 163-9
115. Moremi K, van Rensburg SJ, Fisher LR, et al. Association of an iron-related TMPRSS6 genetic variant c.2207 C > T (rs855791) with functional iron deficiency and its effect on multiple sclerosis risk in the South African population. S Afr J Psychiatry 2013; 19: 120-1
116. Chambers JC, Zhang W, Li Y, et al. Genome-ide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009; 41: 1170-2
117. van Toorn R, Schoeman JF, Solomons R, et al. Iron status in children with recurrent episodes of tumefactive cerebral demyelination. J Child Neurol 2010; 25: 1401-7
118. Davis W, de Kock L, Pretorius K, et al. Development of a single nucleotide polymorphism (SNP) knowledge database: ASMT rs4446909, rs598968 and MTHFR rs1801133 as susceptibility alleles for depression. Afr J Psychiatry 2011; Abstract:5
119. Dewey FE, Chen R, Cordero SP, et al. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet 2011; 7: e1002280
120. Lajugie J, Mukhopadhyay R, Schizas M, et al. Complete genome phasing of family quartet by combination of genetic, physical and population-based phasing analysis. PLoS One 2013; 8: e64571
121. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2007; 35: D61-5
122. Chen R, Butte AJ. The reference human genome demonstrates high risk of type 1 diabetes and other disorders. Pac Symp Biocomput 2011: 231-42
123. Kotze MJ, Schorn D, Coetzer P. The impact of genetic testing on life insurance. J Genomics Afr Soc 2004; 1: 1-11
124. Hansson MG. Ethics and biobanks. Br J Cancer 2009; 100: 8-12
125. Cordell S. The biobank as an ethical subject. Health Care Anal 2011; 19: 282-94
126. Wright GE, Koornhof PG, Adeyemo AA, Tiffin N. Ethical and legal implications of whole genome and whole exome sequencing in African populations. BMC Med Ethics 2013; 28: 14-21
127. Choudhury A, Hazelhurst S, Meintjes A, et al. Population-specific common SNPs reflect demographic histories and highlight regions of genomic plasticity with functional relevance. BMC Genomics 2014; 15: 437
128. Yu JH, Jamal SM, Tabor HK, Bamshad MJ. Self-guided management of exome and whole-genome sequencing results: changing the results return model. Genet Med 2013; 15: 684-90
129. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical evaluation incorporating a personal genome. Lancet 2010; 375: 1525-35
130. Patel CJ, Sivadas A, Tabassum R, et al. Whole genome sequencing in support of wellness and health maintenance. Genome Med 2013; 5: 1-13